Here is a summary of Nick Norwitz’s 8 statements from the last hour of this video, which he believes are true.
These 8 statements summarize his research with Dave Feldman on keto, cholesterol, heart disease, LMHR, Oreos, and the “lipid energy model”.
(These are his words, not mine. The numbers are his. I am paraphrasing him as closely as possible, but usually not directly quoting him. I recommend actually listening to the last hour of the video if you have the time.)
- ApoB is causal of heart disease, and necessary for it to occur.
If you have zero ApoB, then atherosclerosis is not possible.
- ApoB alone is not sufficient for heart disease to occur.
Some people will have high ApoB but never develop atherosclerosis.
LMHR is a case where the question of whether high ApoB alone is sufficient is currently being tested in an on-going prospective cohort study.
- All things being equal, lowering ApoB will tend to lower CVD risk.
- Lowering ApoB is not needed for all patients with high ApoB, in part, because all interventions come with trade offs.
- Lower levels of ApoB can associate with higher all cause mortality.
This is the famous J-shaped curve for LDL. This J-shaped curve disappears when you properly account for confounders and reverse causality. After these corrections, what you then see is that lower ApoB is associated with lower all-cause mortality. Nick explains all of this.
- The act of reducing ApoB can causally reduce mortality and extend healthspan.
- The LMHR phenotype represents unique physiological causes of high ApoB, and this underlying physiology may impact absolute risk.
He clarifies that he is not saying that the TG/HDL ratio is causally protective by itself. It’s the LMHR phenotype as a whole that might allow for higher ApoB without the same size increase in risk that you would see in the general population.
- In LMHR as a specific subpopulation, the absolute benefits of lowering ApoB are unknown and more information is needed to better tailor individual care.
▶
